Have a feature idea you'd love to see implemented?
Let us know!

- Stocks
- Healthcare
- NASDAQ: SPRO

Price (delayed)

$1.24

Market cap

$67.02M

P/E Ratio

3.65

Dividend/share

N/A

EPS

$0.34

Enterprise value

$8.43M

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

SPRO's revenue has soared by 118% YoY and by 7% from the previous quarter

The gross profit has soared by 118% YoY and by 7% from the previous quarter

The EPS has surged by 183% year-on-year but it has declined by 23% since the previous quarter

The equity has increased by 47% year-on-year but it has declined by 16% since the previous quarter

SPRO's quick ratio is down by 32% year-on-year and by 18% since the previous quarter

The net income has contracted by 25% from the previous quarter

What are the main financial stats of SPRO

Market
Valuations
Earnings

Shares outstanding

54.05M

Market cap

$67.02M

Enterprise value

$8.43M

Price to earnings (P/E)

3.65

Price to book (P/B)

0.83

Price to sales (P/S)

0.56

EV/EBIT

0.42

EV/EBITDA

0.42

EV/Sales

0.07

Revenue

$118.46M

EBIT

$20.05M

EBITDA

$20.2M

Free cash flow

-$14.38M

Per share
Balance sheet
Liquidity

EPS

$0.34

Free cash flow per share

-$0.27

Book value per share

$1.49

Revenue per share

$2.2

TBVPS

$2.78

Total assets

$149.88M

Total liabilities

$69.38M

Debt

$4.94M

Equity

$80.5M

Working capital

$76.59M

Debt to equity

0.06

Current ratio

2.68

Quick ratio

3.13

Net debt/EBITDA

-2.9

Margins
Efficiency
Dividend

EBITDA margin

17.1%

Gross margin

100%

Net margin

14.7%

Operating margin

13.1%

Return on assets

11.5%

Return on equity

20.7%

Return on invested capital

49.3%

Return on capital employed

19.2%

Return on sales

16.9%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Spero Therapeutics stock price performed over time

Intraday

0%

1 week

-5.34%

1 month

-9.49%

1 year

7.83%

YTD

-15.65%

QTD

-7.46%

How have Spero Therapeutics's revenue and profit performed over time

Revenue

$118.46M

Gross profit

$118.46M

Operating income

$15.56M

Net income

$17.46M

Gross margin

100%

Net margin

14.7%

The net margin has surged by 179% year-on-year but it has declined by 30% since the previous quarter

SPRO's operating margin has surged by 155% year-on-year but it is down by 33% since the previous quarter

SPRO's revenue has soared by 118% YoY and by 7% from the previous quarter

The gross profit has soared by 118% YoY and by 7% from the previous quarter

What is Spero Therapeutics's growth rate over time

What is Spero Therapeutics stock price valuation

P/E

3.65

P/B

0.83

P/S

0.56

EV/EBIT

0.42

EV/EBITDA

0.42

EV/Sales

0.07

The EPS has surged by 183% year-on-year but it has declined by 23% since the previous quarter

The price to book (P/B) is 67% less than the 5-year quarterly average of 2.5 and 8% less than the last 4 quarters average of 0.9

The equity has increased by 47% year-on-year but it has declined by 16% since the previous quarter

SPRO's revenue has soared by 118% YoY and by 7% from the previous quarter

SPRO's P/S is 96% below its 5-year quarterly average of 14.1 and 20% below its last 4 quarters average of 0.7

How efficient is Spero Therapeutics business performance

The return on sales has surged by 191% year-on-year but it has declined by 28% since the previous quarter

SPRO's ROIC has soared by 118% YoY but it is down by 40% QoQ

The return on assets has declined by 32% since the previous quarter

Spero Therapeutics's ROE has decreased by 31% from the previous quarter

What is SPRO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for SPRO.

How did Spero Therapeutics financials performed over time

SPRO's total assets is 116% higher than its total liabilities

SPRO's total liabilities has surged by 57% year-on-year but it is down by 2.9% since the previous quarter

SPRO's total assets has soared by 52% YoY but it is down by 11% QoQ

The debt is 94% smaller than the equity

The equity has increased by 47% year-on-year but it has declined by 16% since the previous quarter

The debt to equity has contracted by 45% YoY but it has grown by 20% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.